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Background: Recently, the concept of recurrent implantation failure (RIF) in assisted reproductive technology has
been enlarged. Chronic uterine inflammation is a known cause of implantation failure and is associated with high
matrix metalloproteinase (MMP) activity in uterine cavity flushing. MMP activity of women with RIF has been
reported to be higher than that of fertile women. In the present retrospective study we evaluated the efficacy of
treatment for high MMP activity in the uterine cavity of patients with RIF.
Methods: Of the 597 patients recruited to the study, 360 patients underwent MMP measurements and 237 patients
did not (control group). All patients had failed to become pregnant, despite at least two transfers of good-quality
embryos. Gelatinase MMP-2 and MMP-9 activity in uterine flushing fluid was detected by enzymology (MMP test).
All samples were classified into two groups (positive or negative) based on the intensity of the bands on the
enzyme zymogram, which represents the degree of MMP activity. Patients who tested positive on the initial test
were treated for 2 weeks with a quinolone antibiotic and a corticosteroid, and subsequently underwent a second
MMP test. Negative results on the second MMP tests after treatment and subsequent rates of pregnancy and
miscarriage were used to evaluate the efficacy of treatment. Data were analyzed by the Mann–Whitney U-test and
the chi-square test.
Results: Of the patients who underwent the MMP test, 15.6% had positive results (high MMP activity). After
treatment, 89.3% of patients had negative results on the second MMP test. These patients had a significantly better
pregnancy rate (42.0%) than the control group (26.6%), as well as a lower miscarriage rate (28.5% vs 36.5%,
respectively).
Conclusions: A 2-week course of antibiotics and corticosteroids effectively improves the uterine environment
underlying RIF by reducing MMP activity.
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Uterine flushingBackground
In recent decades, many infertile couples, who otherwise
would not have been able to have children, have bene-
fited considerably from assisted reproductive technology
(ART). However, despite the selection of morphologic-
ally good embryos for transfer, there are still some
women who fail to become pregnant. Recently, the con-
cept of recurrent implantation failure (RIF) has emerged* Correspondence: toshiohamatani@z3.keio.jp
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reproduction in any medium, provided the orbecause the implantation process remains the least
understood step in ART. It is known that the success of
embryo implantation depends primarily on the quality of
the embryos transferred. Nonetheless, embryo quality
alone cannot fully explain all cases of RIF, particularly in
young women, whose embryos should be of good quality
[1,2].
Uterine receptivity is another factor crucial for successful
implantation. Numerous studies have sought to identify
clinically useful markers to indicate a receptive uterine
state. However, it is difficult to select useful molecular
biomarkers associated with reproductive failure becausetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of a complex network of mediators, including cell ad-
hesion molecules (e.g. integrins and cadherins), prosta-
glandins, and cytokines (e.g. leukemia inhibitory factor
[LIF] and epithelial growth factor [EGF]).
Chronic endometrial inflammation is a known cause
of implantation failure. Indeed, chronic and mild inflam-
mations are often seen in unfavorable uterine conditions
other than infectious diseases. For example, the number
of macrophages and T cells, which mainly secrete in-
flammatory cytokines, is increased in the endometria of
women with an implanted intrauterine device (IUD) [3],
and the contraceptive activity of the IUD is brought
about by the maintenance of this environment, which is
unfavorable for implantation. As another example,
implantation rates following IVF-ET are lower in
patients with hydrosalpinx compared with rates in those
with unexplained or male sterility because of the leakage
of hydrosalpinx fluid (HF), which contains leukocytes
and inflammatory cytokines such as interleukin (IL)-8,
IL-12, IL-α, and tumor necrosis factor (TNF)-α, contrib-
utes to the deterioration of the intrauterine environ-
ment, leading to implantation failure [4-6]. Thus,
chronic and mild uterine inflammation induces inflam-
matory cells and alters the expression and subtle balance
of various molecules, without any overt clinical symp-
toms, contributing to implantation failure.
In the present study, we focused on matrix metal-
loproteinases (MMPs) as candidate biomarkers of chronic
and mild uterine inflammation. The MMPs are a family of
zinc-dependent proteolytic enzymes that play a major role
in the degradation and rebuilding of the extracellular
matrix (ECM), as well as in cell migration. Abnormal
MMP expression is involved in the pathogenesis of
autoimmune diseases, cancer, endometriosis, and other
inflammatory diseases [7], although MMPs are also cru-
cial for the normal physiology of the reproductive sys-
tem [8-10]. Of the >20 types of MMPs, MMP-2 and
MMP-9 are representative gelatinases that are present
in human uterine endometrial stroma [11,12]. Both MMP-
2 and MMP-9 play an integral role in human embryo im-
plantation and are the main rate-limiting enzymes in
ECM remodeling during implantation. However, MMP-2
and MMP-9 hyperactivity is associated with an unfavor-
able uterine environment, similar to that seen with endo-
metrial inflammation, because successful implantation
depends on a tight balance between the activation and in-
hibition of MMPs [13,14]. Inagaki et al. reported signifi-
cantly higher intrauterine MMP-2 and MMP-9 activity,
as well as IL-β levels, in women with RIF compared with
fertile women [15]. These observations suggest that
MMP activity is a sensitive biomarker of an unfavorable
uterine environment for implantation, such as chronic
endometritis.Accordingly, we hypothesized that treatment of the
chronic intra-uterine inflammation underlying excessive
MMP activity may improve uterine receptivity for trans-
ferred embryos. Therefore, in the present retrospective
study, we evaluated the efficacy of anti-inflammatory
treatment, comprising of corticosteroids and antibiotics,




The present study was performed between July 2006 and
June 2011 on 597 RIF patients (see Figure 1). All
patients had undergone at least two transfers of good-
quality cleavage or blastocyst-stage embryos, but had
failed to become pregnant. The definition of RIF varies
among different infertility clinics [16]. For example, the
2005 ESHRE PGD Consortium proposed that RIF be
defined as “>3 embryo transfers with high-quality em-
bryos or the transfer of ≥10 embryos in multiple trans-
fers; exact numbers to be determined by each centre”
[17]. In our clinic, almost 80% of embryos transferred in
recent years have been blastocysts (Table 1), which has
resulted in better pregnancy outcomes. In 2005, the clin-
ical pregnancy rate at first embryo transfer in our clinic
was 39.7% following the transfer of at least one good-
quality embryo; the clinical pregnancy rate following a
second embryo transfer (after failure of the first) was
also good at 37.1%. Based on these data, in our clinic
most patients whose embryos are of good quality are
likely get pregnant after two embryo transfers. There-
fore, in the present study we defined RIF as “≥2 embryo
transfers with high-quality embryos” and recommended
patients undergo an MMP test after two failed embryo
transfers. In the present study, “good-quality” embryos
were defined as those that were higher than Grade BB
according to Gardner’s criteria [18] or higher than Grade
G2 according to Veeck’s criteria [19]. In each case, one
or two embryos were selected for transfer. Both fresh
and vitrified–thawed embryo transfer cycles were
included in the present study. A clinical pregnancy was
confirmed by transvaginal ultrasound observation of a
gestational sac.
The 597 patients included in the present study were
divided into two groups based on whether they had
undergone the MMP test, which measured MMP-2 and
MMP-9 activity in uterine flushing fluid: 360 patients
underwent the MMP test after repeated unsuccessful
transfers, whereas the remaining 237 did not (Group C;
control group). Of the patients who underwent the
MMP test (see below), those with higher MMP activity
(score ≥5; Group P) were treated for 2 weeks with an
oral corticosteroid plus an antibiotic. After treatment,
the patients underwent a second MMP test to evaluate
Recurrent implantation failures
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(Group C; n = 237)
Figure 1 Flow chart of the study design. In all, 597 patients with RIF were recruited and divided into two groups based on whether or not
they agreed to undergo the matrix metalloproteinase (MMP) test. Patients with MMP scores ≥5 were deemed to have a positive response (Group P)
and were treated with a corticosteroid and an antibiotic for 2 weeks. Patients with low MMP scores (<5) were determined as negative (Group N).
Patients in Group P were given a second MMP test after the treatment and were divided into two subgroups: Group Pr (patients who had again
positive results and were considered as resistant to the treatment) and Group Pe (patients in whom the treatment was effective). Patients who did not
undergo an MMP test comprised the control group (Group C). Patients in all groups underwent another embryo transfer procedure and the outcomes
were compared among the four groups.
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results of the second MMP test, Group P patients were
further subdivided into those who were medication
resistant (Group Pr) and those in whom the treatment
was effective (Group Pe). All patients then underwent
the next round of embryo transfers, with the outcomes
evaluated in terms of the clinical pregnancy and miscar-
riage rates.
Patients ≥43 years of age were excluded from this
study even if a good-quality embryo was obtained. Allpatients underwent transvaginal ultrasound scanning
and hysterosalpingography, and those with findings
suggestive of macropolyps, submucosal myomas, or
anomalies of the uterine cavity were examined further
by hysteroscopy. To confirm diagnoses of leiomyoma,
adenomyosis, or other organic dysfunctions, magnetic
resonance imaging (MRI) was often used. Endometrial
biopsies were performed only in those women with
abnormal genital bleeding or with findings of uterine
endometrial thickening (≥15 mm). Patients diagnosed as
Table 1 Clinical characteristics of two patients groups,






No. patients 360 237
Age (years) 38.1 ± 3.6 37.9 ± 3.6 NS
Prior to intervention
Day 3 serum FSH (mIU/L) 9.67 ± 3.09 9.68 ± 3.50 NS
Total no. transfers 2.28 2.14 NS
Total no. embryos transferred 3.27 3.11 NS
% Blastocysts 76.7 78.4 NS
No. embryos transferred during the
last procedure
1.66 1.69 NS
Where appropriate, data are given as the mean ± SD.
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hyperplasia, leiomyoma, adenomyosis, or endometrial
polyps, were excluded from the present study, because a
previous report has already demonstrated that uterine
flushing samples from women with uterine complica-
tions have higher MMP activity than samples from
women without complications [20]. Patients with uterine
cavity anomalies were also excluded from the study.
The present study was approved by the Ethics Commit-
tees of the Japanese Institution for Standardizing Assisted
Reproductive Technology. Samples were collected only
from those patients who provided informed consent.positive
MMP test 1 
negative
cycle 1 cycle 2 





MMP test 1 
cycle 1 cycle 2 
Figure 2 A schedule of the MMP tests, the medication and the next e
patients were divided into two groups, Group N (Panel a) and Group P (Pa
week treatment composed of antibiotics and corticosteroids at the next pr
the 2nd MMP test at the mid luteal phase of the same cycle, whereas Grou
cycle (the next cycle after the completion of the treatment), Group P patieUterine flushing fluid
Samples were collected at the mid luteal phase, the fifth
to seventh day post-ovulation, which is considered as an
implantation window. The method used to irrigate the
uterine cavity was as described previously [15,20-22],
using an 8 Fr Foley catheter and a syringe filled with 5
mL saline solution. The catheter was first inserted into
the uterine cavity through the cervix and then connected
to the syringe. Subsequently, ≤5 mL saline solution was
injected into the cavity and aspirated immediately with-
out contamination by the vaginal and cervical fluids.
The samples collected were centrifuged at 1000g for 10
min to remove blood corpuscles, large-sized protein
molecules, and other impurities. The supernatant was
collected and stored at −80°C until use.
Gelatin zymography for MMP-2 and MMP-9 activity
Gelatin zymography was performed according to
methods of Fridman et al. [23], with the slight modifica-
tions of Kleiner and Stetler-Stevenson [21]. Gelatin (final
concentration 1 mg/mL) was incorporated into the
running polyacrylamide gel containing 10% acrylamide
(Bio-Rad, CA,USA), 25% Tris buffer (1.5 mol/L, pH 8.8),
0.4% sodium dodecyl sulfate (SDS; Sigma-Aldrich Japan,
Tokyo, Japan), 0.3% ammonium peroxodisulfate (APS;
Sigma-Aldrich Japan, Tokyo, Japan), and 0.1% N,N,N,
N-tetramethylethylendiamine (TEMED; Sigma-Aldrich
Japan, Tokyo, Japan). The stacking gel contained 2%Embryo Transfer
cycle 3
MMP test 2 Embryo Transfer
cycle 3 
mbryo transfer. According to the results of the first MMP test, all the
nel b). Group P patients who had shown a positive result had a two-
oliferative phase (panel b). After the treatment, Group P patients had
p N patients did not have the 2nd test (Panel a). In the subsequent
nts had the next embryo transfers.
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SDS, 0.4% APS, and 0.1% TEMED, and was put on the
top of the running gel. The same volume of sample
buffer, consisting of 17.5% SDS, 7% sucrose, and bro-
mophenol blue, was added to each sample. Then, 10 μL
of each sample was loaded into individual wells and
proteins were electrophoresed for approximately 1 h at
200 V. After electrophoresis, the gels were washed five
times for 5 min each time in a Tris-based solution
consisting of 3% Triton X-100 (Wako, Osaka, Japan).
The gels were then washed three times and incubated
for 48 h at 37°C in a solution containing 5.8% Tris–HCl,
1.7% Tris base, 0.1% NaN3, 0.7% CaCl22H2O, and 5% of
100 μM ZnCl2. After incubation, the gels were stained
for 6 h with 0.1% Coomassie brilliant blue.
The presence of gelatinases (MMP-2 and MMP-9) was
confirmed by their inhibition using EDTA and o-
phenanthroline. Other MMPs that can be detected by
casein rather than gelatin zymography (e.g. MMP-1,
MMP-3, and MMP-7) were not detected in diluted fluid
from the uterine cavity.
Quantitation of MMPs on zymograms
All samples were diluted 20-fold before being run on the
gels. When clear bands were seen against the blue gel
background, gelatinase activity was determined on the
basis of the intensity of those bands. Individual bands
were identified on the gels for proMMP-2, active MMP-
2, proMMP-9, active MMP-9, and dimeric MMP-9.
Zymograms can be quantitated by densitometric ana-
lysis, but this is accurate only at picogram levels of
MMPs when the bands on the zymograms are very faint.
Because of the high gelatinase activity in uterine flushing
fluid, an alternative semiquantitative technique was used
to assess gelatinase activity in this study, rather than
densitometric measurement which can underestimate
the intensity of strong bands [24]. Two independent
observers scored the intensity of each band by visual
inspection from 0 (no band) to 5 (very strong). A total
MMP score for each sample was achieved by adding the
scores for each band in that sample. To confirm the
reliability of the method of evaluation, we performed
preliminary studies in which three observers independ-
ently scored the intensity of bands in >100 samples. The
results indicated a concordance rate of total scores
≥95%. In addition, the incidence of a ≥2 difference in
total scores among the three observers was ≤2%; the
incidence of a ≥3 difference in total scores was 0%. As a
standard, we used the supernatant of BHK9 breast
carcinoma cell culture in the present study.
MMP scoring system
A total MMP score was represented from 0 to 25 [24].
Since mean total MMP score of RIF patients wasdemonstrated as 5.0 ± 3.1 [15], samples with a score >4
were defined as having high MMP activity and as a posi-
tive result on the MMP test. Samples with scores of 0–4
were deemed negative. All women who tested positive
were recommended to start treatment with an oral
corticosteroid (prednisolone 10 mg/day; Predonisolone®;
TAKEDA, Osaka, Japan) and a quinolone antibiotic
(ofloxacin 300 mg/day; Tarivid®; DAIICHI SANKYO,
Tokyo, Japan). Treatment lasted for 2 weeks. After the
treatment period, samples of uterine flushing fluid were
collected at the next luteal phase and the MMP test
repeated.
Statistical analyses
The outcomes of transfers in the different groups were
evaluated by comparing the clinical pregnancy and
miscarriage rates. Data were analyzed by the Mann–
Whitney U-test and the χ2 test. All analyses were
performed using SPSS version 19 (IBM Japan, Tokyo,
Japan). P < 0.05 was considered to be statistically signifi-
cantly different.
Results
The 597 RIF patients in the present study were divided
into two groups depending on whether they agreed to
undergo an MMP test after receiving a comprehensive
explanation of the procedure. The characteristics of
patients in both groups are summarized in Table 1.
There were no significant differences in age, Day 3
serum FSH levels, total number of transfers, the number
of embryos transferred, or the percentage of blastocysts
(not cleavage-stage embryos) that developed from the
transferred embryos between the two groups before the
treatment intervention.
Figure 3 shows representative results of gelatin zymo-
graphy using the supernatant from uterine flushing fluid.
The previous report had implied that there was no cor-
relation between MMP score and protein concentration
in the flushing fluid of RIF [15]. Therefore all neat sam-
ples were diluted 20-folds before being run on the gels
and the MMP score was defined by the intensity of each
band. In this example, only lane 4 is deemed positive
with totally scored 8 (≥5). Of the patients who agreed to
undergo the MMP test, 15.6% (n=56) were deemed to
have a positive response (Group P); the remaining 84.4%
(n=304) of patients had low (≤4) MMP scores (Figure 4).
After 2 weeks treatment of patients in Group P with an
antibiotic and corticosteroid, 89.3% (n=50) had a nega-
tive response to the second MMP test (Group Pe). The
MMP score remained high in 10.7% (n=6) of patients
(Group Pr).
As indicated in Figure 5, patients in Group Pe had a
higher clinical pregnancy rate than patients in Group C
(21/50 [42.0%] vs 63/237 [26.6%], respectively; P < 0.05).
dimericMMP-9 (180kDa)





Figure 3 A representative image of a gelatin zymogram used for MMP scoring in a MMP test. The lanes represent uterine fluid samples
from individual patients with recurrent implantation failure (RIF). Lanes 1, 2, 3, 4 and 6 were scored 4, 2, 4, 8 and 0, respectively. Lane 5 shows a
result from the standard used in the present study (supernatant of BHK9 breast carcinoma cell culture). Details of the scoring system are
described in the Methods section.
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clinical pregnancy rate than patients who tested negative
to the first MMP test (Group N), although the difference
did not reach statistical significance. The miscarriage
rates in Groups Pe, Pr, N, and C were 6/21 (28.6%), 1/1
(100%), 29/92 (31.5%), and 23/63 (36.5%), respectively.
Although there was a tendency for a lower miscarriage
rate in Group Pe compared with Group C patients, the




























Figure 4 The MMP test results before and after the treatment of pati
positive test result (Group P). These patients were then treated with a corti
test. Most patients (89.3%) became negative (Group Pe) after the treatmentDiscussion
Numerous studies have reported on the roles of various
molecules in ensuring a receptive endometrium and
uterine milieu [25-29]. Some studies have used uterine
flushing as a simple and minimally invasive technique to
assess the cytokine concentration of uterine secretions
around the time of implantation in vivo [15,20,24,30,31].
Lopata et al. used zymography to measure MMP-2 and







ents with RIF. Prior to the treatment, 15.6% of patients showed a
costeroid and an antibiotic for 2 weeks and subjected to another MMP

























Figure 5 Clinical pregnancy rate after the next embryo transfer
for the four groups of RIF patients. Group Pe, a positive initial
MMP test, but a negative second MMP test after the treatment;
Group Pr, a positive initial MMP test, and a positive second MMP test
despite the treatment; Group N, a negative response to the MMP
test; Group C, the control group who did not undergo the MMP
test. Patients in Group Pe had a significantly greater pregnancy rate
than patients in Groups N and C (*P < 0.05).
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[24]. Using this MMP scoring system, another study
showed that overexpression of MMP-2 and MMP-9 is
associated with increased IL-1β levels in RIF patients
[15]. This previous study suggests that chronic uterine
inflammation contributes to implantation failure because
IL-1β is a representative inflammatory cytokine and an
inducer of MMPs. In other words, chronic uterine
inflammation is considered to be a major cause of RIF
and high MMP activity.
The present study investigated whether treatment of
an unfavorable uterine environment in women with high
MMP scores could normalize MMP activity and improve
rates of successful implantation. We hypothesized that
antibiotic and corticosteroid treatment for the chronic
inflammation responsible for MMP overactivity would
reduce MMP scores in uterine flushings, improve the
uterine environment for implantation, and consequently
improve clinical pregnancy outcomes in patients with
RIF. The results of the present study strongly support
our hypothesis. After treatment, most patients in Group
P (i.e. those with RIF and a positive result on the first
MMP test) had a negative response to the second MMP
test. Moreover, there were better clinical pregnancy rates
and a tendency for a decrease in miscarriage rates in this
group compared with Groups C and N.
There are some issues that require further discussion.
First is the question of the effects of uterine flushings
themselves on implantation. There have been some trials
investigating improved pregnancy outcomes following
uterine endometrial injury or uterine cavity flushing. In
these studies, local injury to the endometrium, such asendometrial biopsy or curettage, is usually applied before
the cycle used for embryo transfer and has been shown
to improve the chances of successful implantation
[32,33]. In contrast, uterine flushing or injection of
medium into the uterine cavity is usually performed dur-
ing the same cycle as embryo transfer [34]. The effect of
simple flushing of the uterine cavity remains contentious
[35,36]. In the present study, uterine flushing was
performed once for Group N, but twice for Group P.
Regardless of the number of uterine flushings, in all
cases they occurred in cycles other than those used for
embryo transfer. Therefore, we believe that any effect of
the uterine flushing on embryo implantation is likely to
be very limited. The second is regarding the broad
effects of corticosteroids on the uterine environment.
Although we used a corticosteroid to control uterine
inflammation, including non-infectious endometritis, in
the present study, the corticosteroid has a myriad of
effects other than its anti-inflammatory actions. It has
been reported that the high numbers of uterine natural
killer cells (uNK) in the endometria of women with
recurrent miscarriage were reduced following the ad-
ministration of corticosteroids [37,38]. Because uNK
cells secrete not only various cytokines, such as TNF-α,
IFN-γ, TGF-β1 and IL-1β, but also MMP-2 and MMP-9
[5], the reduction in MMP scores in the present study
may be due, in part, to a reduction in the number of
uNK cells.
The third is the choice of a control group. If Group Pe
is compared with Group N, there was a tendency for a
higher pregnancy rate in Group Pe after treatment. This
could be due to differences between Groups Pe and N in
terms of the underlying cause of RIF. For example, the
likely cause of RIF in MMP-positive patients is high
MMP activity related to inflammation, whereas RIF in
MMP-negative patients may be due to something other
than inflammation. Therefore, after elimination of the
cause of RIF by medication, Group Pe patients had a bet-
ter pregnancy rate than Group N, who did not undergo
any treatment for the cause of RIF. In the present study,
we chose Group C as the control group. Patients in
Group C did not undergo any medical intervention. In
contrast, patients in Group Pe were identified as having
high MMP activity in the setting of RIF and subse-
quently underwent treatment to correct high MMP
activity. By comparing these two groups, our aim was to
determine whether the intervention was effective in
improving pregnancy rates in RIF. Strictly speaking, the
present study should have included a more appropriate
control group consisting of patients matched with those
in Group P and treated with placebo. However, there
was a large number of patients enrolled in the present
study and there was clear change in the MMP test
results from positive to negative after treatment in
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the 2-week treatment period was sufficiently effective in
normalizing the receptivity of the uterus.
Recently, benign endometrial pathologies have been
linked to implantation failure and infertility [39-41].
Indeed, Inagaki et al. [20] have reported that MMP
scores of patients with benign uterine complications,
such as leiomyoma, adenomyosis, or endometrial polyps,
are higher than in the control group. In the present
study, those who have such uterine complications were
excluded. However, we did undertake another inves-
tigation about RIF with uterine complications (see
Additional file 1: Figure S1), which showed that the
same treatment for 2 weeks was also effective to reduce
the high MMP scores in the RIF patients with uterine
complications. To date, the exact mechanisms by which
these uterine disorders often limit fertility remain
unclear, but changes in the endometrial immune and
molecular environment have been suggested as a pos-
sible cause [41]. A marked increase in the density of
macrophages and natural killer (NK) cells in endometrial
stromal cells has been observed in the uteri of women
with adenomyosis [42]. Both macrophages and uterine
NK cells are known to be able to release inflammatory
cytokines. Presumably these uterine disorders may bring
about a condition similar to that of chronic inflamma-
tion in the endometrium, resulting in an induction of
MMP activity and MMP production by endometrial
stromal cells in response to the macrophages and other
inflammatory cytokines [11,12].
Chronic endometritis is the most frequent inflam-
matory condition of the uterine endometrium that is
thought to be related to infertility and spontaneous
abortion [43,44]. The prevalence of chronic endometritis
in the general population is estimated to range between
0.8% and 19.0% [45]. In patients undergoing ART, the
prevalence of chronic endometritis has been reported to
be approximately 15%, or up to 42% of patients with RIF
[46,47]. Thus, there is considerable variation in the
reported prevalence of chronic endometritis. This may
be due to the fact that mild chronic endometritis is often
clinically silent, as well as to difficulties in diagnosing
the condition based on histopathological examination or
using a hysteroscope [48,49]. However, the MMP test
used in the present study is able to detect inflammatory
conditions caused by mild and chronic endometritis.
The overexpression of MMPs is induced by any type of
inflammatory condition, and not just infection, hyperpla-
sia or carcinoma, whereas the appearance of many other
inflammatory cells and mediators is sometimes tempo-
rary and specifically dependent on the cause of the
inflammation. As such, the MMP test can be used to
detect various causes of inflammation that may create
an unfavorable environment for implantation.In the present study, only approximately 16% of all
patients tested positive on the first MMP test, despite
the sensitivity of the test. This rate is lower than
expected based on the reported frequency of chronic
endometritis in RIF patients. However, we need to take
into account the advanced maternal age of the patients
recruited to the present study; older patients are more
likely to have embryos with chromosomal abnormalities.
Indeed, it has been reported [50] that the frequency of
aneuploid embryos is higher in older RIF patients (mean
age 39.8 years), similar to the mean patient age of 38.1
years in the present study; specifically, the rate of aneu-
ploidy in oocytes and blastocysts was 65.5% and 45.2%,
respectively. Thus, of the possible causes of RIF, embry-
onic factors, particularly chromosomal abnormalities,
become more important with increasing maternal age.
Taking this into consideration, the fact that 16% of
women were positive to the first MMP test in the
present study is not necessarily low and indicates that,
although not a major cause of RIF, high MMP activity is
likely to contribute to a considerable number of cases of
RIF. The results of the present study show that an
inflammatory uterine environment can be detected by
the MMP test and can be treated successfully to improve
uterine receptivity.Conclusions
The MMP test using uterine flushing fluid and the newly
designed treatment strategy of a 2-week course of anti-
biotics and corticosteroids is likely to be useful for women
with RIF. However, further studies, including prospective
studies, are needed to clarify a causal relationship between
the medication and pregnancy outcomes. In addition, the
routine use of a corticosteroid is not recommended before
further studies have been conducted to confirm its effect
against uterine non-infectious inflammation in RIF.Additional file
Additional file 1: Figure S1. Results of the matrix metalloproteinase
(MMP) test for recurrent implantation failure (RIF) patients with mild
uterine complications.Abbreviations
MMP: Matrix metalloproteinase; RIF: Recurrent implantation failure.
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